United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - tablet, coated - 3.125 mg - carvedilol is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) [see clinical studies (14.1)] . carvedilol is indicated for the management of essential. it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol is contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status asthmaticus have been reported following single doses of carvedilol. - second- or third-degree av block - sick sinus syndrome - severe bradycardia (unless a permanent pacemaker is in place) - patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. such patients should first be weaned from intravenous therapy before initiating carvedilol - p

Canada - English - Health Canada

jamp pharma corporation - carvedilol - tablet - 3.125mg - carvedilol 3.125mg - beta-adrenergic blocking agents

Canada - English - Health Canada

jamp pharma corporation - carvedilol - tablet - 6.25mg - carvedilol 6.25mg - beta-adrenergic blocking agents

Canada - English - Health Canada

jamp pharma corporation - carvedilol - tablet - 25mg - carvedilol 25mg - beta-adrenergic blocking agents

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

medicamen biotech ltd. - carvedilol - tablets - 25mg

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets, usp are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) [see clinical studies (14.2) ]. carvedilol tablets, usp is indicated for the management of essential hypertension [see clinical studies (14.3) ]. it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2) ]. carvedilol is contraindicated in the following conditions: pregnancy category c. studies performed in pregnant rats and rabbits given carvedilol revealed increased post-implantation loss in rats at doses of 300 mg/kg/day (50 times the maximum recommended human dose [mrhd] as mg/m2 ) and in rabbits at doses of 75 mg/kg/day (25 times the mrhd as mg/m2 ). in the rats, there was also a decrease in fetal body weight at the maternally toxic dose of 300 mg/kg/day (50 times the

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - carvedilol 25mg;   - tablet - 25 mg - active: carvedilol 25mg   excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone - carvedilol sandoz is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - carvedilol - oral tablet - 6.25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - carvedilol - oral tablet - 6.25mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - carvedilol - oral tablet - 6.25mg